US19243B1026 - Common Stock
COGNITION THERAPEUTICS INC
NASDAQ:CGTX (9/20/2024, 8:00:00 PM)
After market: 0.5795 0 (-0.02%)0.5796
-0.03 (-4.89%)
Cognition Therapeutics, Inc. is a clinical stage neuroscience company, which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 25 full-time employees. The company went IPO on 2021-10-08. The firm is investigating its lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies and dry age-related macular degeneration (dry AMD). Its lead product candidate, CT1812, is an investigational orally delivered, small molecule modulator that penetrates the blood-brain and blood-retina barriers and binds selectively to the sigma-2 receptor (S2R) complex; and through its modulation of S2R restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. The company is developing other product candidates in the area of synucleinopathies.
COGNITION THERAPEUTICS INC
Suite 261, 2403 Sidney Street
Pittsburgh PENNSYLVANIA
P: 14127701621
Employees: 25
Website: https://cogrx.com/
PURCHASE, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company...
PURCHASE, N.Y., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company...
CGTX stock results show that Cognition Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Here you can normally see the latest stock twits on CGTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: